Drugs · acquisition-cost intelligence
Zyclara
imiquimod· ingredient imiquimodAntivirals· IMIQUIMOD 2.5 mg/g; IMIQUIMOD 37.5 mg/g
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$117.98
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per GM — the trend nobody else shows. 5 weeks.
2025-07-232026-05-20
Same-ingredient options by acquisition cost
Other imiquimod products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.
| Product | NADAC / GM | vs this |
|---|---|---|
| Imiquimod | $0.69561 | −$117.28 |
Medicare Part D coverage · CY2026
On 21 plan formularies · typical tier 4
Prior auth 0% · Step therapy 5% · Quantity limit 62% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.